Journal
VACCINES
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/vaccines11081291
Keywords
Mycoplasma hyopneumoniae; multi-antigen; chimeric vaccine; immune responses
Categories
Ask authors/readers for more resources
In this study, a multi-antigen chimera (L9m6) was constructed and its immunogenic and antigenic properties were assessed in a murine model. The chimeric vaccine induced significant cellular immune responses and high production of antibodies against Mycoplasma hyopneumoniae, suggesting its potential for the prevention and control of porcine enzootic pneumonia.
Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industry. Cellular immunity plays a key role in the prevention and control of porcine enzootic pneumonia. Therefore, the development of a more efficient vaccine that confers a strong immunity against M. hyopneumoniae is necessary. In this study, a multi-antigen chimera (L9m6) was constructed by combining the heat-labile enterotoxin B subunit (LTB) with three antigens of M. hyopneumoniae (P97R1, mhp390, and P46), and its immunogenic and antigenic properties were assessed in a murine model. In addition, we compared the effect of individual administration and multiple-fusion of these antigens. The chimeric multi-fusion vaccine induced significant cellular immune responses and high production of IgG and IgM antibodies against M. hyopneumoniae. Collec-tively, our data suggested that rL9m6 chimera exhibits potential as a viable vaccine candidate for the prevention and control of porcine enzootic pneumonia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available